Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Propranolol 3mg/5ml oral liquid
0204000R0AACTCT
|
Propranolol hydrochloride | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Propranolol 4mg/5ml oral liquid
0204000R0AADHDH
|
Propranolol hydrochloride | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Propranolol 6mg/5ml oral liquid
0204000R0AADDDD
|
Propranolol hydrochloride | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Propranolol 80mg/5ml oral liquid
0204000R0AACNCN
|
Propranolol hydrochloride | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Rapranol SR 160mg capsules
0204000R0BXABAB
|
Rapranol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Rapranol SR 80mg capsules
0204000R0BXAAAA
|
Rapranol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Slo-Pro 160mg capsules
0204000R0BUAAAB
|
Slo-Pro | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 10mg/5ml oral solution
0204000R0BVABCX
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 40mg/5ml oral solution
0204000R0BVADDB
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 50mg/5ml oral solution
0204000R0BVACCY
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 5mg/5ml oral solution
0204000R0BVAACW
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.